Teva has bolstered its respiratory portfolio in the US after launching the first generic version of Viatris’ Perforomist(formoterol fumarate) inhalation solution 20mcg/2ml vial.
The Israeli firm’s launch coincides with the expiry on 22 June of six patents shielding the treatment for chronic obstructive pulmonary disease
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?